BDBM693814 DOTA-NT-20.3::US20240287046, Compound C-1::US20240287046, in vitro binding assay ref

SMILES CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)N(C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)NC(C)=O)C(C)(C)C)C(O)=O

InChI Key InChIKey=XFKZVGLQBLOEFL-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 693814   

TargetNeurotensin receptor type 1(Human)
Full-Life Technologies HK

US Patent
LigandPNGBDBM693814(US20240287046, in vitro binding assay ref | DOTA-N...)
Affinity DataIC50: 32.2nMAssay Description:The binding affinities of test compounds were determined by a radioligand competitive binding assay using 177Lu labeled C-1 as the reference radiolig...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/12/2024
Entry Details
US Patent